本文選題：乳腺浸潤性導管癌 + CXCL16��； 參考：《昆明醫(yī)科大學》2017年碩士論文

【摘要】：目的:本實驗通過檢測乳腺浸潤性導管癌患者的癌組織及癌旁組織中CXCL16蛋白的濃度,比較二者之間的差異。同時探討乳腺浸潤性導管癌患者的臨床特征與癌組織中表達的CXCL16蛋白濃度之間的關系。方法:本實驗研究對象為2015年6月至2016年8月于昆明醫(yī)科大學第一附屬醫(yī)院乳腺外科診治,穿刺病理確診為乳腺浸潤性導管癌并手術,術后石蠟報告確診乳腺浸潤性導管癌患者40例,分別收集癌組織、癌旁組織,分為2組:實驗組(癌組織40例),對照組(癌旁組織40例)。采用酶聯(lián)免疫吸附(ELISA)的實驗方法,分別測定實驗組及對照組中CXCL16蛋白的濃度,分析其濃度與乳腺浸潤性導管癌之間的相關性。根據癌組織中CXCL16蛋白的濃度分析其與乳腺浸潤性導管癌不同的TNM分期、復發(fā)轉移危險度分級、淋巴結是否轉移、分子分型、年齡、絕經與否、乳腺炎病史等臨床特征之間是否存在相關性。實驗數據采用SPSS19.0統(tǒng)計學軟件進行統(tǒng)計分析,統(tǒng)計數據分析采用方差分析和t檢驗。結果:1.CXCL16蛋白在乳腺浸潤性導管癌患者的癌組織中的表達明顯高于癌旁組織,且表達存在顯著的統(tǒng)計學差異(P=0.0019)。2.CXCL16蛋白的表達在有乳腺炎病史的乳腺浸潤性導管癌患者中的表達明顯高于無乳腺炎病史的患者,且表達存在顯著的統(tǒng)計學差異(P=0.000)。3.CXCL16蛋白在TNM分期越高、復發(fā)轉移危險度越高、有淋巴結轉移的乳腺浸潤性導管癌患者中的表達高于低TNM分期、低復發(fā)轉移危險度及無淋巴結轉移的患者,且表達存在統(tǒng)計學差異(P值0.05)。4.CXCL16蛋白的表達在不同分子亞型、不同年齡、絕經與否的乳腺浸潤性導管癌患者中無統(tǒng)計學差異(P值0.05)。結論:1.CXCL16蛋白的濃度在乳腺浸潤性導管癌患者的癌組織中明顯高于癌旁組織,提示CXCL16蛋白與乳腺浸潤性導管癌之間存在相關性。2.CXCL16蛋白的表達在有乳腺炎病史的乳腺浸潤性導管癌患者的癌組織中較無乳腺炎病史的患者高,提示既往有乳腺炎病史的患者患乳腺癌的機率可能增加。3.乳腺浸潤性導管癌患者的癌組織中CXCL16蛋白的濃度與乳腺癌的TNM分期、復發(fā)轉移危險度分級、淋巴結轉移間存在相關性,隨著乳腺浸潤型導管癌的惡性程度增高,CXCL16蛋白的濃度升高,其可能作為乳腺癌惡性程度、浸潤轉移的評估指標之一,且對其預后有一定的輔助預測作用。4.乳腺浸潤性導管癌患者的癌組織中的CXCL16蛋白表達與患者年齡、絕經與否、不同的分子分型之間未發(fā)現(xiàn)相關性。
[Abstract]:Aim: to detect the concentration of CXCL16 protein in breast infiltrating ductal carcinoma and its adjacent tissues. At the same time, the relationship between the clinical features of breast invasive ductal carcinoma and the expression of CXCL16 protein in breast cancer tissue was investigated. Methods: from June 2015 to August 2016, breast surgery was performed in the first affiliated Hospital of Kunming Medical University. Forty cases of breast invasive ductal carcinoma were diagnosed by paraffin wax after operation, and were collected and divided into two groups: the experimental group (40 cases) and the control group (40 cases). The concentration of CXCL16 protein in the experimental group and the control group was determined by Elisa and the correlation between the concentration and the invasive ductal carcinoma of breast was analyzed. According to the concentration of CXCL16 protein in cancer tissues, the TNM staging, the risk of recurrence and metastasis, lymph node metastasis, molecular type, age, menopause or not were analyzed. Whether there is a correlation between clinical features such as mastitis history. The experimental data were analyzed by SPSS19.0 software, and the statistical data were analyzed by ANOVA and t test. Results 1. The expression of CXCL16 protein in breast invasive ductal carcinoma was significantly higher than that in adjacent tissues. The expression of CXCL16 protein in breast infiltrating ductal carcinoma with history of mastitis was significantly higher than that in patients with no history of mastitis. The higher the TNM stage, the higher the risk of recurrence and metastasis. The higher the expression of CXCL16 protein in breast invasive ductal carcinoma with lymph node metastasis was, the higher the expression of CXCL16 protein was in breast invasive ductal carcinoma with lymph node metastasis. In patients with low risk of recurrence and metastasis and no lymph node metastasis, there was no significant difference in the expression of P value 0.05).4.CXCL16 protein in patients with breast invasive ductal carcinoma with different molecular subtypes, age, menopause or not. Conclusion the concentration of CXCL16 protein in breast invasive ductal carcinoma is significantly higher than that in adjacent tissues. 2. The expression of CXCL16 protein in breast invasive ductal carcinoma with history of mastitis was higher than that in patients with no history of mastitis, suggesting that the expression of CXCL16 protein in breast invasive ductal carcinoma was significantly higher than that in breast invasive ductal carcinoma with history of mastitis. The results suggest that patients with previous history of mastitis may have an increased risk of breast cancer. The concentration of CXCL16 protein in breast invasive ductal carcinoma was correlated with TNM stage, risk of recurrence and metastasis, lymph node metastasis. With the increase of malignant degree of invasive ductal carcinoma of breast, CXCL16 protein may be used as one of the evaluation indexes of malignant degree, invasion and metastasis of breast cancer, and it may be helpful to predict the prognosis of breast cancer. There was no correlation between the expression of CXCL16 protein and age, menopause or not, and different molecular typing in breast invasive ductal carcinoma.
【學位授予單位】：昆明醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R737.9

【參考文獻】

相關期刊論文 前10條

1 ;中國抗癌協(xié)會乳腺癌診治指南與規(guī)范(2015版)[J];中國癌癥雜志;2015年09期

2 湯紅平;劉芳;陳國艷;盧翔宇;陳瑩瑩;黃犁;;趨化因子CXCL16在乳腺癌中的表達及其意義[J];中華乳腺病雜志(電子版);2014年06期

3 倪韻碧;曾婉珊;謝文杰;;乳腺癌分子分型的研究進展[J];中華病理學雜志;2014年07期

4 史斌浩;任敏;;女性乳腺癌的主要危險因素[J];中國腫瘤外科雜志;2014年02期

5 陳萬青;張思維;曾紅梅;鄭榮壽;鄒小農;趙平;吳良有;李光琳;赫捷;;中國2010年惡性腫瘤發(fā)病與死亡[J];中國腫瘤;2014年01期

6 方業(yè)穎;雷倩倩;李燕;陳念永;;非分泌型CXCL16在乳腺癌細胞系中的表達及對其生物學特性的影響[J];四川大學學報(醫(yī)學版);2013年04期

7 Yu Huang;Jia Zhang;Zhu-Mei Cui;Jing Zhao;Ye Zheng;;Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes incervical in traepithelial neoplasia and cervical cancer[J];Chinese Journal of Cancer;2013年05期

8 王云萱;趙紅;張清媛;;CXC趨化因子亞族及其受體與乳腺癌相關性的研究進展[J];臨床腫瘤學雜志;2013年04期

9 周雯慧;劉越;胡衛(wèi)東;司蓮蓮;;趨化因子及其受體CXCL16/CXCR6在人肺癌轉移中的作用[J];中華微生物學和免疫學雜志;2011年12期

10 諸葛欣;孟艷玲;孫寧;馮淑芝;王卉;王麗莉;張?zhí)N;;CXCL16對小鼠Matrigel種植體內促血管新生的作用[J];細胞與分子免疫學雜志;2010年11期

，

本文編號：1935661